These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6896123)

  • 21. Tumoral calcinosis with hyperphosphatemia.
    Mahadevan S; Adhisivam B; Kumar CN
    Indian J Pediatr; 2005 Oct; 72(10):889-90. PubMed ID: 16272668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial tumoral calcinosis: a forty-year follow-up on one family.
    Carmichael KD; Bynum JA; Evans EB
    J Bone Joint Surg Am; 2009 Mar; 91(3):664-71. PubMed ID: 19255228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ; Mericq V
    Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 2002 Moyer Award. Metabolic effects of vitamin D on serum calcium, magnesium, and phosphorus in pediatric burn patients.
    Wray CJ; Mayes T; Khoury J; Warden GD; Gottschlich M
    J Burn Care Rehabil; 2002; 23(6):416-23. PubMed ID: 12432318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uremic tumoral calcinosis: preliminary observations suggesting an association with aberrant vitamin D homeostasis.
    Quarles LD; Murphy G; Econs MJ; Martinez S; Lobaugh B; Lyles KW
    Am J Kidney Dis; 1991 Dec; 18(6):706-10. PubMed ID: 1962658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Posttransplant regression of uremic tumoral calcinosis].
    de Alarcón RM; Palomares M; Marfil A; Asensio C
    Nefrologia; 2007; 27(3):378-81. PubMed ID: 17725459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol.
    Llach F; Felsenfeld AJ; Haussler MR
    N Engl J Med; 1981 Jul; 305(3):117-23. PubMed ID: 6894630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumoral calcinosis: clinical and metabolic response to phosphorus deprivation.
    Davies M; Clements MR; Mawer EB; Freemont AJ
    Q J Med; 1987 Jun; 63(242):493-503. PubMed ID: 3659264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of massive tumoral calcinosis of the ischium in a dialysis patient after treatment with reduced calcium dialysate and i.v. administration.
    Apostolou T; Tziamalis M; Christodoulidou C; Fountas P; Billis A
    Clin Nephrol; 1998 Oct; 50(4):247-51. PubMed ID: 9799070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria.
    Van Den Berg CJ; Kumar R; Wilson DM; Heath H; Smith LH
    J Clin Endocrinol Metab; 1980 Nov; 51(5):998-1001. PubMed ID: 6893460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin in chronic renal failure.
    Franck H; Keck E; Issa S; Krüskemper HL; von Lilienfeld-Toal H
    Exp Clin Endocrinol; 1988 May; 91(2):202-6. PubMed ID: 3409970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aminoaciduria in chronic renal failure--its relationship to vitamin D and parathyroid status.
    Phillips ME; Havard J; Otterud B
    Am J Clin Nutr; 1980 Jul; 33(7):1541-5. PubMed ID: 6893104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and genetic analysis of idiopathic normophosphatemic tumoral calcinosis in 19 patients.
    Zuo QY; Cao X; Liu BY; Yan D; Xin Z; Niu XH; Li C; Deng W; Dong ZY; Yang JK
    J Endocrinol Invest; 2020 Feb; 43(2):173-183. PubMed ID: 31535357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ratio of parathyroid hormone to 1,25-dihydroxycholecalciferol in early renal failure.
    Lucas PA; Brown RC; Woodhead JS; Coles GA
    Kidney Int Suppl; 1983 Dec; 16():S171-4. PubMed ID: 6588249
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders.
    Frishberg Y; Topaz O; Bergman R; Behar D; Fisher D; Gordon D; Richard G; Sprecher E
    J Mol Med (Berl); 2005 Jan; 83(1):33-8. PubMed ID: 15599692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
    Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
    Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome.
    Auwerx J; De Keyser L; Bouillon R; De Moor P
    Nephron; 1986; 42(3):231-5. PubMed ID: 3753749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of strontium ranelate administration on calcium metabolism in female patients with postmenopausal osteoporosis and primary hyperparathyroidism.
    Carnevale V; Del Fiacco R; Romagnoli E; Fontana A; Cipriani C; Pepe J; Minisola S
    Calcif Tissue Int; 2013 Jan; 92(1):15-22. PubMed ID: 23080188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function.
    Goldstein DA; Haldimann B; Sherman D; Norman AW; Massry SG
    J Clin Endocrinol Metab; 1981 Jan; 52(1):116-21. PubMed ID: 6969729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.